A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED

Exclusion Criteria

• •1. Have a known ocular infection that is deemed to be active requiring therapeutic intervention
• •2. Present with a corneal surface defect in either eye that is directly attributed to an infectious etiology (bacterial, viral, fungal and/or protozoal) that has not fully resolved and/or treatment has not been completed
• •3. Present with evidence of corneal ulceration/melting involving the posterior third of the stroma and/or perforation in either eye
• •4. Have a blepharitis or meibomian gland disease in the study eye that is deemed to be clinically relevant and/or active
• •5. Have a history of ocular surgery or any ocular procedure(s) not meeting the designated washout time
• •6. Have any other ocular disease requiring topical ocular medication in the affected eye
• •7. Have a presence or history of any ocular or systemic disorder or condition that could interfere the safety or efficacy of the study treatment, or the interpretation of the study results
• •8. Have a known hypersensitivity to one of the components of the study or procedural medications (e.g., NEXAGON, fluorescein)
• •9. Participated in an interventional clinical drug or device trial within 28 days prior to Day 1
• •10. Use of the medications presented in the protocol that are prohibited in the study.